CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis
Authors
Keywords
Pharmacogenomics, Breast cancer, Cytochrome P450 2D6, Tamoxifen, Meta-analysis
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 72, Issue 2, Pages 287-303
Publisher
Springer Nature
Online
2013-05-27
DOI
10.1007/s00280-013-2195-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
- (2014) N Fleeman et al. HEALTH TECHNOLOGY ASSESSMENT
- Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand
- (2013) Chonlaphat Sukasem et al. Asian Pacific Journal of Cancer Prevention
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
- (2012) Solai Elango Damodaran et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients
- (2012) Andreas Trojan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance
- (2012) Kristin Josefine Ruth Dickschen Frontiers in Pharmacology
- The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
- (2011) L. K. Teh et al. AAPS Journal
- Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
- (2011) In Hae Park et al. BREAST CANCER RESEARCH AND TREATMENT
- Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials
- (2011) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese
- (2011) Kazuma Kiyotani et al. HUMAN MOLECULAR GENETICS
- Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
- (2011) Hyung Seok Park et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
- (2011) T. L. Lash et al. JNCI-Journal of the National Cancer Institute
- Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen
- (2010) Timothy L. Lash et al. ACTA ONCOLOGICA
- Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
- (2010) Bostjan Seruga et al. BREAST CANCER RESEARCH AND TREATMENT
- Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen
- (2010) Nava Siegelmann-Danieli et al. BREAST CANCER RESEARCH AND TREATMENT
- Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy
- (2010) Alastair M. Thompson et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
- (2010) W. Schroth et al. CLINICAL CANCER RESEARCH
- Impact ofCYP2D6*4genotype on progression free survival in tamoxifen breast cancer treatment
- (2010) Julia Carolin Stingl et al. CURRENT MEDICAL RESEARCH AND OPINION
- Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen
- (2010) Roberta Ferraldeschi et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias
- (2010) Karsten Knobloch et al. JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY
- Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response
- (2010) Kazuma Kiyotani et al. Pharmacogenetics and Genomics
- Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial
- (2010) D Serrano et al. PHARMACOGENOMICS JOURNAL
- The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
- (2009) Monique J. Bijl et al. BREAST CANCER RESEARCH AND TREATMENT
- Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users
- (2009) A. S. Dieudonné et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
- (2009) T. Ramón y Cajal et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
- (2009) Masatsugu Okishiro et al. CANCER
- Early and Locally Advanced Breast Cancer: Diagnosis and Treatment National Institute for Health and Clinical Excellence Guideline 2009
- (2009) J. Yarnold CLINICAL ONCOLOGY
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment
- (2009) T. Toyama et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
- (2009) J M Rae et al. PHARMACOGENOMICS JOURNAL
- Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
- (2008) Y. Xu et al. ANNALS OF ONCOLOGY
- Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
- (2008) Kazuma Kiyotani et al. CANCER SCIENCE
- Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients
- (2008) W. G. Newman et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now